High response rate to PD-1 blockade in desmoplastic melanomas

Nature

Volumn 553, Issue 7688, 2018, Pages 347-350

  Eroglu, Zeynep ^a,b   Zaretsky, Jesse M ^a   Hu Lieskovan, Siwen ^a   Kim, Dae Won ^b,c   Algazi, Alain ^d   Johnson, Douglas B ^e   Liniker, Elizabeth ^f   Kong, Ben ^g   Munhoz, Rodrigo ^h,i   Rapisuwon, Suthee ^j   Gherardini, Pier Federico ^k   Chmielowski, Bartosz ^a   Wang, Xiaoyan ^a   Shintaku, I Peter ^a   Wei, Cody ^a   Sosman, Jeffrey A ^e,p   Joseph, Richard W ^l   Postow, Michael A ^h,i   Carlino, Matteo S ^f,g,m   Hwu, Wen Jen ^c   Scolyer, Richard A ^f,m,n   Messina, Jane ^b   Cochran, Alistair J ^a   Long, Georgina V ^f,m,o   Ribas, Antoni ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f MELANOMA INSTITUTE AUSTRALIA   (Australia)

^g WESTMEAD HOSPITAL   (Australia)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

^j GEORGETOWN UNIVERSITY   (United States)

^k PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY   (United States)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^o ROYAL NORTH SHORE HOSPITAL   (Australia)

^p NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BMS 936559; CD8 ANTIGEN; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; NEUROFIBROMIN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ANTIBODY; APOPTOSIS; DISEASE RESISTANCE; GENE; GENE EXPRESSION; HISTOLOGY; IMMUNE RESPONSE; MUTATION; TUMOR; ULTRAVIOLET RADIATION;

ADAPTIVE IMMUNITY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DESMOPLASTIC MELANOMA; DRUG RESPONSE; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MUTATIONAL LOAD; NF1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STROMA; TUMOR INVASION; VERY ELDERLY; WHOLE EXOME SEQUENCING; ANTAGONISTS AND INHIBITORS; BIOPSY; CD8+ T LYMPHOCYTE; CELL CYCLE CHECKPOINT; CYTOLOGY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METABOLISM; MUTATION;

B7-H1 ANTIGEN; BIOPSY; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOTHERAPY; MELANOMA; MUTATION; NEUROFIBROMIN 1; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES;

EID: 85040827832     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature25187     Document Type: Article

References (30)

1. Shain, A. H. et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat. Genet. 47, 1194-1199 (2015).
2. Ribas, A. et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. J. Am. Med. Assoc. 315, 1600-1609 (2016).
3. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
4. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
5. Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35-44 (2016).
6. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909-1920 (2016).
7. Han, D. et al. Clinicopathologic predictors of survival in patients with desmoplastic melanoma. PLoS One 10, e0119716 (2015).
8. Busam, K. J. et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am. J. Surg. Pathol. 28, 1518-1525 (2004).
9. Alexandrov, L. B. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
10. Wiesner, T. et al. NF1 mutations are common in desmoplastic melanoma. Am. J. Surg. Pathol. 39, 1357-1362 (2015).
11. Krauthammer, M. et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat. Genet. 47, 996-1002 (2015).
12. Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175-180 (2017).
13. Akbani, R. et al. Genomic classification of cutaneous melanoma. Cell 161, 1681-1696 (2015).
14. Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188-201 (2017).
15. Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017).
16. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
17. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819-829 (2016).
18. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
19. Daud, A. I. et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102-4109 (2016).
20. Frydenlund, N. et al. Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. Mod. Pathol. 30, 357-369 (2017).
21. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
22. Akbay, E. A. et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355-1363 (2013).
23. Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227-231 (2016).
24. Dorand, R. D. et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353, 399-403 (2016).
25. Kataoka, K. et al. Aberrant PD-L1 expression through 3′ -UTR disruption in multiple cancers. Nature 534, 402-406 (2016).
26. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
27. Jiang, H. et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22, 851-860 (2016).
28. Nghiem, P. T. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N. Engl. J. Med. 374, 2542-2552 (2016).
29. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
30. Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255-265 (2017).